Latest News and Press Releases

CHESTERBROOK, Pa., Sept. 03, 2019 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with...

— Completed enrollment in healthy volunteer QT study, topline data expected in Q4 2019 — — Completed characterization of inactive metabolite — — Remains on track to resubmit NDA in Q1 2020 — ...

— Enrollment for healthy volunteer QT study ongoing, topline data on schedule for Q4 2019 readout — — Company remains on track to resubmit NDA for oliceridine in Q1 2020 — — Cash runway as...

CHESTERBROOK, Pa., July 31, 2019 (GLOBE NEWSWIRE) -- Trevena, Inc. (NASDAQ: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with...

CHESTERBROOK, Pa., June 27, 2019 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with...

CHESTERBROOK, Pa., June 24, 2019 (GLOBE NEWSWIRE) -- Trevena, Inc. (NASDAQ: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with...

CHESTERBROOK, Pa., June 20, 2019 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN) (“Trevena” or the “Company”), a biopharmaceutical company focused on the development and commercialization of novel...

CHESTERBROOK, Pa., May 29, 2019 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients...

— Company announces receipt of FDA feedback on healthy volunteer study protocol and analysis plan for oliceridine — – Study on track to initiate by end of June – Company to host conference call...

— Company announces submission of oliceridine healthy volunteer study protocol and analysis plan to FDA —  — Successful fundraising extends cash runway into 3Q 2020 —Company to host conference call...